Holen Sie sich die Stockscreener-App
24.53
2.39%
-0.60
Handel nachbörslich:
24.53
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - 富途牛牛
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32 - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates - MSN
Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD By Investing.com - Investing.com Australia
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD - Investing.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
JMP Securities Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $38.00 - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
UBS Raises Price Target for ACADIA Pharmaceuticals to $36 - AInvest
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Acadia Pharmaceuticals shares rise 1.05% intraday after UBS raised price target to $36. - AInvest
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $40 - 富途牛牛
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Shares Surge 3.07% to New Peak on Q2 Earnings, Patent Wins - AInvest
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN
Acadia Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel - Investing.com Canada
Mizuho Maintains Neutral Rating, Raises Price Target for ACADIA Pharmaceuticals to $24 - AInvest
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $38 - 富途牛牛
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings By Investing.com - Investing.com Canada
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings - Investing.com
Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP - TipRanks
Acadia Pharmaceuticals price target raised to $27 from $23 at BofA - TipRanks
Acadia Pharmaceuticals Beats Q2 Earnings ForecastsNews and Statistics - IndexBox
Acadia: Q2 Earnings Snapshot - New Haven Register
Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP - Investing.com Australia
Acadia Pharmaceuticals shares rise 2.10% premarket after FDA approves expanded indication for AJOVY. - AInvest
Acadia Pharmaceuticals Raises Guidance As Sales Climb In Q2 - Finimize
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts By Investing.com - Investing.com Canada
Instagram Rolls Out New Features for Personalized Content Discovery and Sharing - AInvest
ACADIA Pharmaceuticals Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) - Seeking Alpha
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts - Investing.com
Transcript : ACADIA Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Acadia Pharmaceuticals Q2 Earnings Fall, Revenue Rises - MarketScreener
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Neuren Pharma shares soar on Q2 royalties growth - Capital Brief
Revamping Acadia - BioCentury
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):